Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).
The postponed ACIP meeting comes barely a week after Robert F. Kennedy, Jr. was confirmed as Secretary of Health and Human ...
At two Senate confirmation hearings, Kennedy played down his well-publicised questioning of the safety of childhood vaccines ...
Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...
GSK (GSK) announced that the China National Medical Products Administration, CNMPA, has accepted for review the new drug application for the ...
The story has been updated to correct the FDA approval date to Friday, February 14 On Friday, February 14, the FDA approved ...
A second federal judge paused Trump's order against gender-affirming care for youth. ( AP) Johnson & Johnson aims to have a ...
The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active ...
Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...
Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...
GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage ...
A second pentavalent vaccine for preventing meningococcal disease has been approved by the U.S. FDA. GSL plc’s Penmenvy will now go up against Pfizer Inc.’s Penbraya, which had a two-year head start ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback